Orphenadrine
Disipal, Invagesic, Norflex, Norgesic (orphenadrine) is a small molecule pharmaceutical. Orphenadrine was first approved as Norflex on 1982-01-01. It is used to treat muscle cramp, muscle rigidity, myositis, pain, and spasm amongst others in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aspirin
+
Caffeine
+
Orphenadrine citrate
Orphenadrine citrate
Orphenadrine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DISIPAL | 3M | N-010653 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| norgesic | ANDA | 2022-05-17 |
| orphenadrine citrate, aspirin and caffeine | ANDA | 2023-06-19 |
| orphengesic forte | ANDA | 2021-04-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| muscle cramp | HP_0003394 | D009120 | — |
| muscle rigidity | HP_0002063 | D009127 | — |
| myositis | EFO_0000783 | D009220 | G72.49 |
| pain | EFO_0003843 | D010146 | R52 |
| spasm | — | D013035 | M62.83 |
| tetanus | EFO_0005593 | D013742 | A35 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M03: Muscle relaxants
— M03B: Muscle relaxants, centrally acting agents
— M03BC: Ethers chemically close to antihistamines, centrally acting muscle relaxants
— M03BC01: Orphenadrine (citrate)
— M03BC51: Orphenadrine, combinations
N: Nervous system drugs
— N04: Anti-parkinson drugs
— N04A: Anticholinergic agents
— N04AB: Ethers chemically close to antihistamines, anticholinergic
— N04AB02: Orphenadrine (chloride)
HCPCS
Code | Description |
|---|---|
| J2360 | Injection, orphenadrine citrate, up to 60 mg |
Clinical
Clinical Trials
900 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 5 | 11 | 17 | 16 | 16 | 62 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 4 | 9 | 16 | 14 | 8 | 48 |
| Cerebral palsy | D002547 | G80 | 2 | 8 | 15 | 4 | 15 | 41 | |
| Torticollis | D014103 | HP_0000473 | F45.8 | 5 | 8 | 10 | 7 | 9 | 37 |
| Muscle spasticity | D009128 | HP_0001257 | 1 | 5 | 11 | 8 | 11 | 36 | |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 2 | 5 | 9 | 7 | 6 | 27 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | 1 | 4 | 10 | 5 | 5 | 24 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | 3 | 2 | 5 | 4 | 3 | 15 |
| Hyperhidrosis | D006945 | HP_0000975 | 3 | 2 | 2 | 4 | 4 | 15 | |
| Blepharospasm | D001764 | G24.5 | 1 | 3 | 5 | 4 | 3 | 14 |
Show 78 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tennis elbow | D013716 | EFO_1001896 | M77.1 | — | — | 5 | — | 3 | 8 |
| Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | 1 | 4 | 2 | — | 2 | 7 |
| Sialorrhea | D012798 | HP_0002307 | K11.7 | — | 5 | 3 | — | 1 | 6 |
| Vulvodynia | D056650 | N94.81 | — | 2 | 3 | — | — | 5 | |
| Temporomandibular joint disorders | D013705 | M26.6 | 1 | 2 | 2 | — | 1 | 5 | |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 5 | 1 | — | — | 5 |
| Headache | D006261 | HP_0002315 | R51 | — | — | 2 | — | 2 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 2 | 1 | — | — | 3 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | 3 | 2 | — | — | 3 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | 2 | 2 | 1 | — | — | 3 |
Show 27 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | 2 | 3 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | 1 | 1 | — | — | 1 | 3 | |
| Neck pain | D019547 | HP_0030833 | M54.2 | 2 | 1 | — | — | 1 | 3 |
| Smiling | D012904 | — | 1 | — | — | 1 | 2 | ||
| Abdominal hernia | D046449 | K46 | — | 1 | — | — | 1 | 2 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | — | 2 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | 2 | — | — | — | 2 |
| Traumatic brain injuries | D000070642 | S06 | — | 2 | — | — | — | 2 | |
| Back pain | D001416 | HP_0003418 | M54 | — | 1 | — | — | 1 | 2 |
| Pruritus | D011537 | HP_0000989 | L29 | 1 | 1 | — | — | 1 | 2 |
Show 49 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | — | — | — | — | 2 |
| Pelvic floor disorders | D059952 | 1 | — | — | — | 1 | 2 | ||
| Hemorrhagic stroke | D000083302 | 1 | — | — | — | — | 1 | ||
| Internal carotid artery dissection | D020215 | 1 | — | — | — | — | 1 | ||
| Vertebral artery dissection | D020217 | I77.74 | 1 | — | — | — | — | 1 | |
| Affect | D000339 | 1 | — | — | — | — | 1 | ||
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Gingival overgrowth | D019214 | K06.1 | 1 | — | — | — | — | 1 | |
| Treatment-resistant depressive disorder | D061218 | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dystonia | D004421 | HP_0001332 | G24 | — | — | — | — | 3 | 3 |
| Esophageal motility disorders | D015154 | K22.4 | — | — | — | — | 2 | 2 | |
| Diffuse esophageal spasm | D015155 | EFO_1001785 | K22.4 | — | — | — | — | 2 | 2 |
| Strabismus | D013285 | HP_0000486 | H50.2 | — | — | — | — | 2 | 2 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | — | — | — | 2 | 2 |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 2 | 2 |
| Hidradenitis suppurativa | D017497 | L73.2 | — | — | — | — | 2 | 2 | |
| Activities of daily living | D000203 | — | — | — | — | 1 | 1 | ||
| Botulism | D001906 | EFO_0005542 | A05.1 | — | — | — | — | 1 | 1 |
| Pancreatic fistula | D010185 | — | — | — | — | 1 | 1 |
Show 30 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ORPHENADRINE |
| INN | orphenadrine |
| Description | Orphenadrine is a tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol. It has a role as a NMDA receptor antagonist, a H1-receptor antagonist, an antiparkinson drug, a parasympatholytic, a muscle relaxant, a muscarinic antagonist and an antidyskinesia agent. It is a tertiary amino compound and an ether. |
| Classification | Small molecule |
| Drug class | sympathomimetics |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccccc1C(OCCN(C)C)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 83-98-7 |
| RxCUI | 7715 |
| ChEMBL ID | CHEMBL900 |
| ChEBI ID | 7789 |
| PubChem CID | 4601 |
| DrugBank | DB01173 |
| UNII ID | AL805O9OG9 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,061 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
47,991 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more